Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

NovaBay Pharmaceuticals (NBY) Consolidated Net Income (2016 - 2025)

Historic Consolidated Net Income for NovaBay Pharmaceuticals (NBY) over the last 17 years, with Q3 2025 value amounting to $40000.0.

  • NovaBay Pharmaceuticals' Consolidated Net Income fell 9376.95% to $40000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$925000.0, marking a year-over-year increase of 5934.07%. This contributed to the annual value of -$124000.0 for FY2024, which is 9681.97% up from last year.
  • According to the latest figures from Q3 2025, NovaBay Pharmaceuticals' Consolidated Net Income is $40000.0, which was down 9376.95% from -$965000.0 recorded in Q4 2024.
  • NovaBay Pharmaceuticals' Consolidated Net Income's 5-year high stood at $642000.0 during Q3 2024, with a 5-year trough of -$8.2 million in Q4 2022.
  • In the last 5 years, NovaBay Pharmaceuticals' Consolidated Net Income had a median value of -$399000.0 in 2023 and averaged -$1.3 million.
  • As far as peak fluctuations go, NovaBay Pharmaceuticals' Consolidated Net Income tumbled by 509367.09% in 2022, and later surged by 25891.09% in 2024.
  • Over the past 5 years, NovaBay Pharmaceuticals' Consolidated Net Income (Quarter) stood at -$158000.0 in 2021, then crashed by 5093.67% to -$8.2 million in 2022, then surged by 65.96% to -$2.8 million in 2023, then skyrocketed by 65.45% to -$965000.0 in 2024, then soared by 104.15% to $40000.0 in 2025.
  • Its Consolidated Net Income stands at $40000.0 for Q3 2025, versus -$965000.0 for Q4 2024 and $642000.0 for Q3 2024.